Reported 12 days ago
Amgen's stock is experiencing a downturn following the release of underwhelming data from two drug studies, raising concerns about the company's performance in the immunology and rare disease sectors. Analysts discuss the implications for Amgen's position relative to its competitors in the biotech market.
Source: YAHOO